It’s ‘Telehealth vs. No Care’: Doctors Say Congress Risks Leaving Patients Vulnerable
Congress’ $1.7 trillion omnibus spending package included a two-year extension of pandemic-era funding that helped telehealth services grow nationwide. But that cash bridge, embraced by those delivering services to patients in rural areas, doesn’t provide much certainty for the future of remote medicine.
KHN Investigation: The System Feds Rely On to Stop Repeat Health Fraud Is Broken
A months-long KHN examination of the system meant to bar fraudsters from Medicaid, Medicare, and other federal health programs found gaping holes and expansive gray areas through which banned individuals slip to repeatedly bilk taxpayer-funded programs.
Buy and Bust: After Platinum Health Took Control of Noble Sites, All Hospital Workers Were Fired
Two Missouri towns are without operating hospitals after private equity-backed Noble Health left both facilities mired in debt, lawsuits, and federal investigations. The hospitals’ new operator, Platinum Health, agreed to buy them in April for $2 and laid off the last employees in early September.
Buy and Bust: Collapse of Private Equity-Backed Rural Hospitals Mired Employees in Medical Bills
The U.S. Labor Department investigates Noble Health after former employees of its shuttered Missouri hospitals say the private equity-backed owner took money from their paychecks and then failed to fund their insurance coverage.
Rural Hospital Rescue Program Is Met With Skepticism From Administrators
A new federal rescue program that pays rural hospitals to shutter underused inpatient units and focus solely on emergency rooms and outpatient care hasn’t generated much interest yet.
Buy and Bust: When Private Equity Comes for Rural Hospitals
Noble Health swept into two small Missouri towns promising to save their hospitals. Instead, workers and vendors say it stopped paying bills and government inspectors found it put patients at risk. Within two years — after taking millions in federal covid relief and big administrative fees — it locked the doors.
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
After years of failure, the Maryland company aims to attract the vaccine-hesitant with an alternative to mRNA shots. But will it find a market?
Fabricantes de medicamentos se niegan a ofrecer descuentos a miles de farmacias contratadas por los hospitales, diciendo que el programa ha crecido más allá de su uso previsto.
As Big Pharma and Hospitals Battle Over Drug Discounts, Patients Miss Out on Millions in Benefits
The number of pharmacies dispensing 340B discounted drugs soared to more than 31,000 this year. Drugmakers struck back by halting some discounts. Hospitals say they are losing millions of dollars — and cutting back services to patients — as a result.
‘No Mercy’ Bonus Episodes: More From Fort Scott, Kansas
Check out the latest bonus episodes from the award-winning “Where It Hurts” podcast.
What the Stalemate on Capitol Hill Means for Your Drug Prices
Despite big 2020 campaign promises to deliver lower costs on prescription drugs, Democrats have failed to unite around a legislative plan.
How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
With real-time data streaming in from highly specialized researchers in the U.S. and abroad, NIH scientists became convinced that boosting the covid-19 vaccine was needed to save lives, prompting the president to announce a plan with a Sept. 20 start date. Scientists at the regulatory agencies weren’t yet convinced. A meeting Friday will determine what happens next. Here’s the story from behind the scenes.
Lo que debes saber sobre el refuerzo de la vacuna contra covid
La administración de Biden anunció el miércoles 18 de agosto planes para ofrecer refuerzos de la vacuna contra covid-19 a todos los adultos estadounidenses a partir del próximo mes.
The White House Says Boosters for All. Here’s What You Need to Know.
Federal officials are preparing to offer those who received Pfizer or Moderna covid vaccines a third dose in September. But the FDA and CDC are still reviewing the data for final clearance.
Mensaje del CEO de Pfizer al público: confíen en nosotros con el refuerzo de la vacuna contra covid
Pfizer anunció su ensayo global de fase 3 sobre una tercera dosis a mediados de julio. La fecha de finalización de ese ensayo es en 2022. Los resultados de la fase 3 suelen ser necesarios antes de la aprobación oficial.
Pfizer CEO to Public: Just Trust Us on the Covid Booster
As pharmaceutical companies declare a need for boosters, scientists and doctors emphasize there’s no proof yet.
Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed
Novavax is a vaccine company that, despite $2 billion in new federal and international funding, still hasn’t come through with a licensed covid vaccine. It hopes it can still help to fight the global covid scourge, but will it deliver?
All agree that covid vaccines are urgently needed to stop the pandemic, but simply waiving patents fails to provide technological know-how and address supply chain challenges.
‘It Didn’t Really Stick With Me’: Understanding the Rural Shrug Over Covid and Vaccines
Fort Scott, Kansas, was hit hard by the pandemic, and it no longer has a hospital. But residents remain skeptical about the impact of the coronavirus.
Pfizer’s Newest Vaccine Plant Has Persistent Mold Issues, History of Recalls
After nearly a decade’s worth of federal inspections, reprimands and corrective action plans, has Pfizer fixed the facility that will be filling vials of its covid vaccine?